Clinical Trial Search

Primary: Atrial Fibrillation (AF) Burden Defined as the Mean Amount of Time Spent in AF Over a Pre-specified Period of Time (Excluding Short AF Episodes of ≤30 Seconds) by the…

Primary: Confirmation of Entrance Block in the Pulmonary Veins — 159; 157 participants

Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants

Primary: Percentage of Participants With Freedom From Primary Safety Events at 12 Months Post-procedure (Acute and Chronic Events) Using the Boston Scientific Cardiac…

Primary: Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients — 6 Participants

Primary: Proportion of Days Covered — 1.0; 0.9 Proportion of days covered — p=0.22

Primary: Number of Participants With Recurrence of Atrial Tachyarrhythmia — 36; 44 Participants — p=0.0016

Primary: Chronic Effectiveness — 56; 26 percentage of participants with success — p=<0.0001

Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants

Primary: The Number of Participants Free From Atrial Fibrillation (AF), Atrial Flutter or Atrial Tachycardia While Off Class I and Class III Antiarrhythmic Drugs for at Least 4…

Primary: Change in AF Burden — 5.6; 5.0; 4.1; 4.3 percentage of time in AF — p=0.520

Primary: Number of Participants With Paroxysmal AF With an Event of Documented Symptomatic Atrial Fibrillation (AF)/Flutter — 129; 135; 140; 123 participants — p=0.263

Primary: Number of Days on Anticoagulation — 24.9 days

Primary: Survival Free of Atrial Fibrillation — 28; 31 participants

Primary: Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)% — 2.8; 4.5 percentage of blood ejected in one beat

Primary: Numbers of Participants Free From AF — 20; 96; 20; 97 Participants

Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants

Primary: AF Detection Rate Within 6 Months — 8.9; 1.4 percentage of participants — p=0.0006

Primary: Composite of All-cause Mortality and Heart Failure Events — 50; 64 Participants

Primary: The Rate of Subjects Who Were Free From Documented Symptomatic Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atrial Flutter (AFL) Episodes Through 12-month…

Primary: Interview Process — 34 Participants

Primary: Unplanned Hospital Admissions for Cardiac Reasons OR Death of Cardiovascular Causes OR Progression to Chronic Atrial Fibrillation — 43; 44 participants

Primary: Proportion of Subjects Who Were Free From Atrial Arrhythmia at One Year. — 10; 18; 29; 20 participants — p=0.048

Primary: Primary Safety Endpoint: Composite Safety Endpoint (CSE) Defined as the Incidence of the Following Early-onset and Late-onset Serious Adverse Events (SAEs) Which Are…

Primary: Recurrence Rate of Atrial Arrhythmias — 8; 14; 7; 1 participants — p=0.047

Primary: Atrial Tachyarrhythmia Recurrence in Participants — 37 participants

Primary: The Rate of AF Through 12 Months in Subjects With a Recent Ischemic Stroke of Presumed Known Origin. — 12.5; 1.8 percentage of participants — p=<0.001

Primary: Primary Safety Endpoint (PSE): Event Rate of Safety Events Post Procedure — 2.3; 2.4 Percentage of participants

Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV

Primary: Number of Participants With Any Primary Adverse Events (PAE) That Occurred Within 7 Days Following Atrial Fibrillation (AF) Ablation Procedure Using HELIOSTAR Catheter…